A single-phase powder formulation for oral suspension

A single-phase powder formulation of omeprazole with buffering agents addresses stability issues, ensuring homogeneity and simplifying administration while maintaining therapeutic efficacy.

WO2026234680A1PCT designated stage Publication Date: 2026-11-12WAYMADE PLC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IN2025/051157
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2025-07-30
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing proton pump inhibitor (PPI) formulations, such as omeprazole, face stability issues due to sensitivity to moisture, heat, and light, leading to degradation and reduced potency, and require multi-phase systems that complicate storage, administration, and dose accuracy.

Method used

A single-phase powder formulation of omeprazole with at least two buffering agents and additional excipients, ensuring homogeneity and stability, suitable for oral suspension, which can be stored and administered as a single unit.

Benefits of technology

The formulation maintains stability and homogeneity, simplifies administration, and reduces impurities, enhancing therapeutic efficacy and shelf life.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a single-phase powder formulation of omeprazole intended for reconstitution as a suspension for oral administration. The formulation comprises omeprazole, at least two buffering agents, and one or more pharmaceutically acceptable excipients, all stored together in a single-phase system. The invention aims to enhance the stability of omeprazole and improve its impurity profile by maintaining omeprazole, buffering agents, and excipients in a unified solid phase.
Need to check novelty before this filing date? Find Prior Art

Description

A single-phase powder formulation for oral suspension

[0001] This application is related to Indian Patent application No. IN202521044536 filed on 8thMay, 2025 and is incorporated herein in its entirety.

[0002] The present invention relates to a single-phase powder formulation for oral suspension comprising omeprazole for oral administration.

[0003] Proton pump inhibitors (PPIs) are prone to stability issues due to their chemical structure, which makes them highly sensitive to moisture, heat, and light. These drugs, such as omeprazole and esomeprazole, are benzimidazole derivatives that degrade rapidly in acidic environments, necessitating the use of enteric coatings or buffering agents to maintain their efficacy. Additionally, PPIs can undergo oxidation and hydrolysis, leading to reduced potency and shelf life. Proper formulation strategies, including the use of stabilizers and controlled storage conditions, are essential to mitigate these stability concerns and ensure therapeutic effectiveness.

[0004] Omeprazole, a proton pump inhibitor (PPI), is widely used to treat gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related disorders. Existing formulations such as those disclosed in EP3799861, ES2283172, EP1905426, WO2024261481, and WO2024030936 primarily rely on multi-phase powder systems requiring separate storage of components and in-situ mixing before administration. These multi-phase systems pose challenges in terms of convenience, dose accuracy, stability, and packaging.

[0005] EP3799861 discloses a two-phase storage-stable omeprazole powder system where different powder mixtures are stored separately and require mixing before constitution. ES2283172 discloses a granular formulation with omeprazole and excipients for extemporaneous suspension preparation. EP1905426 discloses an anti-acid pharmaceutical powder composition with a two-phase powder mix comprising sodium alginate and antacids. WO2024261481 discloses a powder composition for oral suspension comprising a two-phase powder mixture wherein the first phase comprising a PPI, a diluent, a buffering agent, a binding agent, and the second phase comprising a buffering agent, a viscosity enhancer, a diluent, a preservative. WO2024030936 discloses a two-component pharmaceutical composition suitable for a modified-release formulation.

[0006] EP3999066A1 discloses a reconstituted suspension comprising omeprazole along with inactive ingredients such as poloxamer, sodium carboxymethylcellulose, sodium bicarbonate, simethicone emulsion, a preservative, a sweetener, water, and optionally a flavoring and / or coloring agent, wherein the kits containing omeprazole remain stable under refrigerated conditions at 2–8°C.

[0007] Thus, there exists a need for a single-phase, storage-stable omeprazole formulation that maintains homogeneity, enhances stability, and simplifies administration. The present invention addresses these shortcomings.Advantageous Effects of Invention

[0008] The object of the present invention is to provide a powder formulation of omeprazole to be reconstituted as a suspension for oral administration wherein omeprazole and at least two buffering agents are present in a single-phase powder.

[0009] Another object of the present invention is to provide a powder formulation of omeprazole to be reconstituted as a suspension for oral administration wherein omeprazole, at least two buffering agents, and one or more pharmaceutically acceptable excipients are present in a single-phase powder.

[0010] Another object of the present invention is to provide a powder formulation of omeprazole, wherein ompeprazole, at least two buffering agents, and one or more pharmaceutically acceptable excipients are stored together.

[0011] The present invention relates to a single-phase powder formulation of omeprazole to be reconstituted as a suspension for oral administration. The present invention also provides a single-phase powder formulation of omeprazole for oral suspension for pediatric use.

[0012] A single-phase powder formulation for oral suspension comprising omeprazole and at least two buffering agents.

[0013] A single-phase powder formulation for oral suspension comprising omeprazole and at least two buffering agents, wherein pH of the formulation is in range of about 8 to about 9.

[0014] A single-phase powder formulation for oral suspension comprising omeprazole and at least two buffering agents, wherein specified impurities such as Esomeprazole Impurity-6 is not more than 0.5%, Impurity A is not more than 1.5%, preferably not more than 0.5%, and any unspecified impurities are not more than 0.2% when the formulation is stored at 30°C and 65% relative humidity (RH) for at least 6 months, and at 25°C and 60% RH for at least 6 months.

[0015] A single-phase powder formulation for oral suspension comprising omeprazole, at least two buffering agents, and one or more pharmaceutically acceptable excipients selected from a viscosity enhancer, a sweetener, a preservative, a diluent, and a flavoring agent.

[0016] According to another embodiment of the invention, a single-phase powder formulation for oral suspension comprising omeprazole, at least two buffering agents, one or more viscosity enhancer, a sweetener, a preservative, a diluent, and a flavoring agent.

[0017] The term "about", as and when used in this specification, means ±10 % of the mentioned value. As used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise.

[0018] According to the presentation, omeprazole or a free base, free acid, salt, hydrate, ester, amide, enantiomer, isomer, tautomer, polymorph, derivative, or prodrug thereof is present in the range from about 0.1 % w / w to about 2.5 % w / w of the total formulation, preferably in the range from about 0.5% w / w to about 1.5% w / w, more preferably in the range from about 0.3 w / w to about 1.0 w / w.

[0019] According to the present invention, omeprazole or a free base, free acid, salt, hydrate, ester, amide, enantiomer, isomer, tautomer, polymorph, derivative, or prodrug thereof present in the formation has D10 particle size distribution not more than (NMT) 5 µm, D50 particle size distribution NMT 10 µm, D90 particle size distribution NMT 15 µm.

[0020] According to the present invention, a buffering agent is selected from selected from group alkali metal or alkali earth metal of carbonate and bicarbonate, phosphate, citrate, borates, acetates, phthalates, tartrates, and succinates. According to another embodiment of the present invention, a buffering agent is selected from sodium bicarbonate, potassium bicarbonate, calcium carbonate, acetic acid, sodium acetate, citric acid, sodium citrate, sodium phosphate disodium phosphate, sodium hydrogen carbonate, potassium hydrogen carbonate, gluconate, tartrates, 1-methionine, potassium citrate, sodium carbonate anhydrous, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium hydroxide, potassium dihydrogen phosphate, fumaric acid, tartaric acid or any combinations thereof. A single-phase powder formulation according to the present invention comprises at least two buffering agents, preferably two or more buffering agents, more preferable three buffering agents. A single-phase powder formulation according to the present invention comprises a same buffering agent or different buffering agent. For the purpose of the present invention, a buffering agent is sodium bicarbonate, potassium bicarbonate, calcium carbonate or mixture of thereof. For the purpose of the present invention, sodium to potassium bicarbonate ratio is 1:2 to1:2.5. For the purpose of the present invention, a buffering agent is present in the range from about 20% w / w to about 55% w / w of the total formulation, preferably in the range from about 25% w / w to about 55% w / w, more preferably in the range from about 27% w / w to about 45% w / w.

[0021] According to the present invention, a viscosity enhancer is selected from sodium alginate, xanthan gum, carrageenan, gum acacia, gum tragacanth, sodium carboxymethyl cellulose, methylcellulose, bentonite, veegum, carbomers, colloidal silicon dioxide, glucose, fructose, acacia, bentonite, carboxymethyl cellulose sodium, gelatin, guar gum, hydroxyl ethyl cellulose, hydroxyl propyl methylcellulose, polyvinylpyrrolidone, and polyvinyl alcohol, or any combinations thereof. A single-phase powder formulation according to the present invention comprises one or more viscosity enhancer. A single-phase powder formulation according to the present invention comprises more than one viscosity enhancer, preferably two viscosity enhancers. For the purpose of the present invention, a viscosity enhancer is sodium alginate and xanthan gum. For the purpose of the present invention, a viscosity enhancer is present in the range from about 0.5% w / w to about 5% w / w of the total formulation, preferably in the range from about 1% w / w to about 4% w / w.

[0022] According to the present invention, a sweetener is selected from sucralose, mannitol, sucrose, fructose, dextrose, isomalt, sorbitol, sucralose, acesulfame K, aspartame, cyclamate, saccharin, stevia, sucralose, sodium saccharin, xylitol, natural sweeteners such as stevia, or a combination thereof. For the purpose of the present invention a sweetener is sucralose. For the purpose of the present invention, a sweetener is present in the range of about 0.05% w / w to about 1% w / w of the total formulation.

[0023] The present invention includes preservatives that are suitable for use in pharmaceutical preparations, including antimicrobial preservatives. Suitable antimicrobial preservatives include, for example, sodium benzoate, potassium benzoate, calcium benzoate, methyl paraben sodium, ethyl paraben sodium, and mixtures thereof. In some embodiments described herein, the preservative is sodium benzoate, methyl paraben sodium, or a mixture thereof. In some embodiments, the preservative is a mixture of sodium benzoate and methyl paraben sodium. For the purposes of the present invention, a preservative is present in the range of about 0.05% w / w to about 4% w / w, preferably in the range from about 0.1% w / w to about 3% w / w.

[0024] According to the present invention, a diluent is selected from maltitol, xylitol, sorbitol, erythritol, isomalt, lactitol, mannitol, or any combinations thereof. For the purposes of the present invention, a diluent is mannitol, maltitol, and xylitol or combination. For the purposes of the present invention, a diluent is present in the range from about 30% w / w to about 90% w / w of the total formulation, preferably in the range from about 40% w / w to about 85% w / w, more preferably in the range from about 50% w / w to about 70% w / w.

[0025] According to another embodiment, a single-phase powder formulation for oral suspension further comprises a flavoring agent. Suitable flavoring agents include, for example, the following flavors or mixtures thereof: mint, vanilla, banana, apple, orange, pear, peach, strawberry, raspberry, chocolate, lemon, lime, butterscotch, caramel, cherry, and cinnamon. In some embodiments described herein, the flavoring agent is mint flavor, vanilla flavor, or a mixture thereof.

[0026] Omeprazole is the active pharmaceutical ingredient (API) responsible for inhibiting gastric acid secretion by targeting the H+ / K+ ATPase enzyme in the stomach lining. It is typically present in a micronized or enteric-coated form to enhance its stability and bioavailability, as omeprazole is highly susceptible to degradation in acidic environments.

[0027] According to another embodiment, a single-phase powder formulation for oral suspension further comprises an anti-adherent. For the purpose of the present invention an anti-adherent is titanium dioxide, talc, magnesium stearate.

[0028] A single-phase powder formulation for oral suspension comprising:

[0029] Omeprazole,

[0030] at least two buffering agents selected from sodium bicarbonate, potassium bicarbonate, calcium carbonate or mixture of thereof,

[0031] a viscosity enhancer selected from sodium alginate and xanthan gum,

[0032] a sweetener is sucralose,

[0033] a preservative is selected from sodium benzoate and methyl paraben sodium, and

[0034] a diluent is selected from maltitol, xylitol, sorbitol, erythritol, isomalt, lactitol, mannitol, or any combinations thereof.

[0035] A single-phase powder formulation for oral suspension comprises omeprazole a buffering agent, a viscosity enhancer, a sweetener, a preservative, and a diluent, wherein

[0036] omeprazole is present in the range from about 0.1 % w / w to about 2.5 % w / w of the total formulation, preferably in the range from about 0.5% w / w to about 1.5% w / w, more preferably in the range from about 0.3% w / w to about 1.0 w / w,

[0037] at least two buffering agents are present in the range from about 20% w / w to about 55% w / w of the total formulation, preferably in the range from about 25% w / w to about 55% w / w, more preferably in the range from about 27% w / w to about 45% w / w,

[0038] a viscosity enhancer is present in the range from about 0.5% w / w to about 5% w / w of the total formulation, preferably in the range from about 1% w / w to about 4% w / w,

[0039] a sweetener is present in the range of about 0.05% w / w to about 1% w / w of the total formulation,

[0040] a preservative is present in the range of about 0.05% w / w to about 4% w / w, preferably in the range from about 0.1% w / w to about 3% w / w,

[0041] a diluent is present in the range from about 30% w / w to about 90% w / w of the total formulation, preferably in the range from about 40% w / w to about 85% w / w, more preferably in the range from about 50% w / w to about 70% w / w.

[0042] A single-phase powder formulation for oral suspension comprises:

[0043] omeprazole,

[0044] sodium bicarbonate, potassium bicarbonate, calcium carbonate, or combination thereof,

[0045] sodium alginate, xanthan gum, or combination thereof,

[0046] sucralose,

[0047] sodium benzoate, methyl paraben sodium, or combination thereof,

[0048] maltitol.

[0049] According to another embodiment, the process for the preparation of a single-phase powder formulation for oral suspension comprises omeprazole, at least two buffering agents, a viscosity enhancer, a sweetener, a preservative, a flavoring agent, and a diluent is by wet granulation or dry mixing process.

[0050] According to another embodiment, the wet granulation process includes steps of (a) granulating a omeprazole and a buffering agent or agents by using water and / or a solvent such as ethanol and isopropyl alcohol, (b) drying and milling granules of step (a), and (c) mixing granules of step (b) with a buffering agent, a diluent, a viscosity enhancing agent, a preservative, a sweetener, a flavoring agent, and an anti-adherent.

[0051] According to another embodiment, the wet granulation process includes steps of (a) granulating a buffering agent and a viscosity enhancer by using water, (b) drying and milling granules of step (a), and (c) mixing granules of step (b) with omeprazole, a viscosity agent, a diluent, a preservative, a sweetener, a flavoring agent and an anti-adherent.

[0052] The wet granulation process according to present invention does not require the use of any sperate binders to perform the wet granulation process.

[0053] According to another embodiment, the dry mixing process includes steps of mixing omeprazole, at least two buffering agents, a viscosity enhancer, a sweetener, a preservative, a flavoring agent, and a diluent.

[0054] According to another embodiment, the single component powder system can be packed into a suitable packaging bottle like High density polyethylene bottle (HDPE), Polyethylene Terephthalate (PET) bottle, glass bottle, more preferably into heavy weight HDPE bottle.

[0055] According to another embodiment, the single-component powder system was prepared and filled in a 150 cc white opaque HDPE bottle, fitted with a 28 mm polypropylene child-resistant cap with a heat-seal liner. The packaged powder was then stored under stability conditions at 30°C / 65% RH and 25°C / 60% RH for a duration of 6 months. Samples were tested using reverse phase HPLC method for assay, impurity, and dissolution.

[0056] Example 1 and 2: A single-phase powder formulation of omeprazole for oral suspension prepared by wet granulation.Ingredient% W / W(Example 1)% W / W(Example 2)Intra granularOmeprazole0.380.77Sodium Bicarbonate13.5113.51Potassium Bicarbonate13.8213.82Extra-granularPotassium Bicarbonate12.7612.76Sodium Alginate3.263.26Sucralose0.770.77Mint Flavour0.960.96Xanthan Gum0.210.21Sodium Benzoate0.960.96Methyl Paraben Sodium0.450.45Maltitol52.1751.79Titanium Dioxide0.740.74Total100.00100.00Manufacturing Process:

[0057] Sifting: Sodium bicarbonate is sifted through a vibratory sifter with a #40 ASTM sieve.

[0058] Milling: Potassium bicarbonate is milled through a 0.5 mm SS screen using a multi-mill.

[0059] Mixing: Omeprazole with Sodium bicarbonate.

[0060] Dry Mixing and Wet Granulation: Materials are blended in a planetary mixer, granulated with purified water, and mixed thoroughly.

[0061] Drying: The wet granules are dried at 40°C until the target LOD of 1.0% w / w is achieved.

[0062] Final Processing: The dried granules are milled, sifted, and blended with extra-granular ingredients to ensure homogeneity.

[0063] Fill the dried granules of step 6 in a white opaque HDPE bottle fitted with a polypropylene child-resistant cap with a heat-seal liner.

[0064] Example 3: A single-phase powder formulation of omeprazole for oral suspension prepared by wet-granulation and dry mixing.Ingredient% W / WIntra granularOmeprazole0.77Sodium Bicarbonate12.77Calcium Carbonate12.77Extra-granularCalcium Carbonate12.77Sodium Alginate3.26Sucralose0.77Mint Flavour0.96Xanthan Gum0.21Sodium Benzoate0.96Methyl Paraben Sodium0.45Maltitol54.34Total100.00Manufacturing Process: wet granulation process

[0065] Weigh all materials accurately.

[0066] Co-sift omeprazole, Sodium Bicarbonate and Calcium carbonate through 40 # mesh ASTM and load into a planetary mixer and dry mix for 10 min and granulate with purified water.

[0067] Pass wet mass blend though 3.0 mm Multimill screen, Kinfe forward at slow speed.

[0068] Dry wet mass in fluid bed processor at inlet temperature NMT 45°C (LOD NMT 2.0 % at 105°C).

[0069] Pass the dried granules through 0.5 mm Multimill screen, Kinfe forward at slow speed.

[0070] Mix step-5 granules with ASTM 40# sifted sodium alginate and calcium carbonate.

[0071] Pass Maltitol through 0.5 mm Multimill screen at slow speed.

[0072] Co-sift step 7 material with Sucralose, Sodium Benzoate, Xanthan gum, Sodium Methyl-paraben and Mint flavour through 30 # mesh ASTM.

[0073] Mix material of step 6 & 8 for 20 minutes at 12 RPM into double cone blender.

[0074] Fills the dried granules of step 9 in a white opaque HDPE bottle fitted with a polypropylene child-resistant cap with a heat-seal liner.Manufacturing Process: Dry mixing process

[0075] Weigh all materials accurately.

[0076] Co-sift omeprazole and sodium alginate through 40# sieve and mix it well.

[0077] Co-sift step -2 material with Sodium Bicarbonate and Calcium carbonate through 40 # mesh ASTM and mix it well.

[0078] Pass Maltitol through 0.5 mm Multimill screen at slow speed.

[0079] Co-sift step 4 material with Sucralose, Sodium Benzoate, Xanthan gum, Sodium Methyl-paraben and Mint flavour through 30 # mesh ASTM.

[0080] Mix material of step 3 & 5 for 20 minutes at 12 RPM into double cone blender.

[0081] Fill the mix of step 6 in a white opaque HDPE bottle fitted with a polypropylene child-resistant cap with a heat-seal liner.

[0082] Example 4: A single-phase powder formulation of omeprazole for oral suspension prepared by wet granulation as Example 1 and 2.Ingredient% W / WIntra granularOmeprazole0.77Sodium Bicarbonate13.51Potassium Bicarbonate12.77Extra-granularPotassium Bicarbonate13.83Sodium Alginate3.26Sucralose0.77Mint Flavour0.96Xanthan Gum0.21Sodium Benzoate0.96Methyl Paraben Sodium0.45Maltitol52.53Total100.00

[0083] Example 5: A single-phase powder formulation of omeprazole for oral suspension prepared by wet granulation.Ingredient% W / WIntra granularSodium Bicarbonate9.82Sodium alginate3.25Extra-granularOmeprazole0.77Sucralose0.77Mint Flavour0.96Xanthan Gum0.21Sodium Benzoate0.96Methyl Paraben Sodium0.45Maltitol82.82Total100.00Manufacturing Process:

[0084] Sodium Bicarbonate and Sodium alginate were sifted through 40 # mesh ASTM.

[0085] Sodium Bicarbonate and Sodium alginate were mixed and granulated with purified water.

[0086] Wet granules were sifted through 3.0 mm screen size.

[0087] Wet granules were dried 50 °C temperature and passed through 0.5 mm screen size at slow speed.

[0088] Maltitol was milled through 0.5 mm screen at a slow speed.

[0089] Omeprazole was co-sifted with half quantity of maltitol powder through ASTM 40# sieve.

[0090] Above step mixture was co-sifted with Sucralose, Sodium Benzoate, Sodium Methyl-paraben, Mint flavor and half qty. Maltitol Powder through 40 # mesh ASTM.

[0091] Blend the intra-granular part with extra-granular material in blender for 15 min.

[0092] Fills in a white opaque HDPE bottle fitted with a polypropylene child-resistant cap and a heat-seal liner.

[0093] Example 6: A single-phase powder formulation of omeprazole of Example 1 was analyzed in 900 ml of pH 7.4 phosphate buffer at 50 RPM in USP II (Paddle) apparatus and subjected to a stability study of 30°C / 65%RH and 25°C / 60% RH for 6 months. Results are tabulated below:ParametersSpecificationInitial6M30°C / 65%RH25°C / 60% RHAssay (%)Omeprazole90 - 110%97.1103.4103.3Sodium Benzoate80 - 120%82.182.989.5Methyl paraben sodium80 - 120%96.083.1088.7pH-8.298.368.42DissolutionNot less than 80.0% in 30 minutes105.3101102.5Impurities (%)Impurity_BNot more than 0.5%BQLBQLBQLImpurity_INot more than 0.5%NDNDNDImpurity_ENot more than 0.5%0.020.020.02Impurity_ANot more than 0.5%0.050.250.14Desmethoxy OmeprazoleNot more than 0.5%NDNDNDImpurity_GNot more than 0.5%NDNDNDImpurity_FNot more than 0.5%NDNDNDEsomeprazole Imp-6Not more than 0.5%BQL0.150.03UfiprazoleNot more than 0.5%BQLBQLBQLAny unspecified impurityNot more than 0.2%0.010.020.01Total ImpuritiesNot more than 4.0%0.100.560.23

[0094] Example 7: A single-phase powder formulation of omeprazole of Example 2 was analyzed in 900 ml of pH 7.4 phosphate buffer at 50 RPM in USP II (Paddle) apparatus and subjected to a stability study of 30°C / 65%RH and 25°C / 60% RH for 6 months. Results are tabulated below:ParametersSpecificationInitial6M30°C / 65%RH25°C / 60% RHAssay (%)Omeprazole90 - 110%95.093.896.0Sodium Benzoate80 - 120%96.598.096.3Methyl paraben sodium80 - 120%97.893.792.9pH-8.22--DissolutionNot less than 80.0% in 30 minutes92.395.096.5Impurities (%)Impurity_BNot more than 0.5%BQLBQLBQLImpurity_INot more than 0.5%NDNDNDImpurity_ENot more than 0.5%0.020.020.02Impurity_ANot more than 0.5%0.050.080.07Desmethoxy OmeprazoleNot more than 0.5%NDNDNDImpurity_GNot more than 0.5%NDNDNDImpurity_FNot more than 0.5%NDNDNDEsomeprazole Imp-6Not more than 0.5%BQL0.030.01UfiprazoleNot more than 0.5%BQLNDNDAny unspecified impurityNot more than 0.2%BQL0.010.00Total ImpuritiesNot more than 2.0%0.100.170.12

[0095] Example 8: A single-phase powder formulation of omeprazole of Example 3 was analyzed in 900 ml of pH 7.4 phosphate buffer at 50 RPM in USP II (Paddle) apparatus and subjected to a stability study of 30°C / 65%RH and 25°C / 60% RH for 6 months. Results are tabulated below:ParametersSpecificationInitial6M30°C / 65%RH25°C / 60% RHAssay (%)Omeprazole90 - 110%101.8101.299.7Sodium Benzoate90 - 110%10497.194.9Methyl paraben sodium90 - 110%101105.0102.8pH-8.288.38.27DissolutionNot less than 80.0% in 30 minutes99.9104.9104.74Impurities (%)Impurity_BNot more than 0.5%BQLNDNDImpurity_INot more than 0.5%NDNDNDImpurity_ENot more than 0.5%0.020.020.02Impurity_ANot more than 0.5%0.030.080.04Desmethoxy OmeprazoleNot more than 0.5%BQLNDNDImpurity_GNot more than 0.5%NDNDNDImpurity_FNot more than 0.5%NDNDNDEsomeprazole Imp-6Not more than 0.5%BQL0.030.01UfiprazoleNot more than 0.5%0.01NDNDAny unspecified impurityNot more than 0.2%0.040.010.00Total ImpuritiesNot more than 4.0%0.130.160.08

[0096] Example 9: A single-phase powder formulation of omeprazole of Example 5 was analyzed in 900 ml of pH 7.4 phosphate buffer at 50 RPM in USP II (Paddle) apparatus and subjected to a stability study of 30°C / 65%RH and 25°C / 60% RH for 6 months. Results are tabulated below:ParametersSpecificationInitial6M30°C / 65%RH25°C / 60% RHAssay (%)Omeprazole90 - 110%94.694.297.8Sodium Benzoate90 - 110%96.398.997.9Methyl paraben sodium90 - 110%103.295.798.1pH-7.98.428.45DissolutionNot less than 80.0% in 30 minutes95.4 (0.63)92.796.2Impurities (%)Impurity_BNot more than 0.5%0.01BQLBQLImpurity_INot more than 0.5%NDBQLNDImpurity_ENot more than 0.5%0.030.020.02Impurity_ANot more than 0.5%0.040.040.04Desmethoxy OmeprazoleNot more than 0.5%NDNDBQLImpurity_GNot more than 0.5%ND0.03NDImpurity_FNot more than 0.5%ND0.03NDEsomeprazole Imp-6Not more than 0.5%NA0.040.01UfiprazoleNot more than 0.5%NA0.05BQLAny unspecified impurityNot more than 0.2%0.090.230.07Total ImpuritiesNot more than 4.0%0.151.30.24

[0097] The stability data presented in Examples 6 to 9 demonstrate that the single-phase powder formulations according to the present invention, comprising at least two buffering agents (Examples 1 to 3), are more stable and exhibit a better impurity profile compared to the single-phase powder formulation containing omeprazole and only one buffering agent (Example 5). In Example 9 (formulation of Example 5), the level of any unspecified impurity is relatively high—i.e., 0.23% when the formulation is stored at 30°C and 65% relative humidity. In contrast, the formulations according to the present invention show significantly lower levels of unspecified impurities, ranging from 0.01% to 0.02% under the same storage conditions.

Claims

A single-phase powder formulation for oral suspension comprising omeprazole and at least two buffering agents.The single-phase powder formulation as claimed in claim 1, wherein pH of the formulation is in the range of about 8 to about 9.The single-phase powder formulation as claimed in claim 1, wherein Impurity-6 is present not more than 0.5%, Impurity A is present at not more than 1.5% and any unspecified impurities are not more than 0.2% when the formulation is stored at 30°C and 65% relative humidity (RH) for at least 6 months, and at 25°C and 60% RH for at least 6 months.The single-phase powder formulation as claimed in claim 1, wherein the formation comprises one or more viscosity enhancer, a sweetener, a preservative, a diluent, and a flavoring agent.The single-phase powder formulation as claimed in claim 1, wherein the formulation comprises three buffering agents.The single-phase powder formulation as claimed in claim 5, wherein the formulation comprises a same buffering agent or different buffering agent.The single-phase powder formulation as claimed in claim 6, wherein sodium to potassium bicarbonate ratio is 1:2 to1:2.5.The single-phase powder formulation as claimed in claim 7, wherein the buffering agent is selected from sodium bicarbonate, potassium bicarbonate, calcium carbonate or mixture of thereof.The single-phase powder formulation as claimed in claim 8, wherein a buffering agent is present in the range from about 20% w / w to about 55% w / w of the total formulation.The single-phase powder formulation as claimed in claim 7, wherein the formulation comprises: Omeprazole;at least two buffering agents selected from sodium bicarbonate, potassium bicarbonate, calcium carbonate or mixture of thereof;a viscosity enhancer selected from sodium alginate and xanthan gum,a sweetener is sucralose;a preservative is selected from sodium benzoate and methyl paraben sodium; anda diluent is selected from maltitol, xylitol, sorbitol, erythritol, isomalt, lactitol, mannitol, or any combinations thereof.